Intrapleural Natural Beta Interferon in the Treatment of Malignant Pleural Effusions

Rosso, Riccardo; Rimoldi, R; Salvati, Franco; Palma, M. De; Cinquegrana, A.; Nicoló, Guido; Ardizzoni, Andrea; Fusco, U.; Capaccio, Annalisa; Centofanti, Robert; Neri, Monica; Cruciani, A.R.; L, Maisto

doi:10.1159/000226571

Cited by 75 publications

(20 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interleukin-2 (IL-2), interferon-b, and interferon-c (IFN-c) have been tried, with variable success, in the treatment of malignant pleural effusion and mesothelioma [162][163][164][165][166][167]. It is not clear whether the observed responses are due to intrinsic sclerosing activity or, instead, to an immunological effect such as an increased natural killer cell population.…”

Section: Treatment Of Pleurodesis Failurementioning

confidence: 99%

Management of malignant pleural effusions

et al. 2001

View full text Add to dashboard Cite

Section: Treatment Of Pleurodesis Failurementioning

confidence: 99%

Management of malignant pleural effusions

et al. 2001

View full text Add to dashboard Cite

“…Uchida et al (1984) reported that intrapleural instillation with the biological response modifier OK-432 significantly increased autologous tumour killing by tumour-associated large granular lymphocytes. The intrapleural instillation of natural a-interferon was reported to be effective against malignant pleural effusions by Rosso et al (1988). Recently, Markowitz et al (1992) reported on the efficacy of intracavity administration of a-interferon.…”

Section: Patientsmentioning

confidence: 99%

Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study

Goey¹,

Eggermont²,

Punt³

et al. 1995

Br J Cancer

View full text Add to dashboard Cite

S_mmary Twenty-three patients with pleural mesothelioma stage I-IIA were entered in a study of continuous daily intrapleural infusion of interleukin 2 (IL-2) for 14 days, repeated every Intrapleural IL-2 levels were high (>20 000 IU ml-') at levels E and F, while serum levels in most patients were not or barely detectable (<3-30 IU ml-'). Intrapleural IL-2 levels were up to 6000-fold higher than systemic levels. Intrapleural tumour necrosis factor alpha (TNF-a) levels varied greatly and did not correlate with IL-2 dosage. Intrapleural mononuclear cells (MNCs) displayed IL-2-induced lymphokine-activated killer (LAK) activity in all patients. Two patients were not evaluable for response owing to catheter-related problems which precluded the delivery of IL-2. Partial response (PR) occurred in 4 of 21 evaluable patients (19%; 95% confidence interval 5-42%) with a median time to progression of 12 months (range 5-37). Stable disease (SD) occurred in seven patients with a median time to progression of 5 months (range 2-7). There were no complete responses (CRs). The median overall survival was 15.6 months (range 3.0-43). No relationship between the dose of IL-2 and response rate was observed. We conclude that IL-2 given intrapleurally is accompanied with acceptable toxicity and has anti-tumour activity against mesothelioma. In view of the refractory nature of the disease IL-2 may be a treatment option for mesothelioma. A formal phase II study is warranted. Based on the observed toxicity, the lack of dose-response relationship and the immunomodulatory effects seen at relatively low-dose IL-2, the recommended dose for a phase II study is 3 x I06IU day-' using the present treatment schedule.

show abstract

“…In phase II studies, several cytokines, including interferon (IFN)-· [17], IFN-ß [18], tumor necrosis factor-· (TNF) [19] and interleukin-2 (IL-2) [20], have shown their activity in the treatment of neoplastic effusions. According to preliminary data [20,21], IL-2 intracavitary injection would seem to represent one of the most effective strategies.…”

Section: Introductionmentioning

confidence: 99%

Progress Report on the Palliative Therapy of 100 Patients with Neoplastic Effusions by Intracavitary Low-Dose Interleukin-2

et al. 2001

View full text Add to dashboard Cite

Objective: Several cytokines, particularly IL-2 and interferons, are thought to be effective in the palliative therapy of neoplastic effusions. We report on the activity and toxicity of intracavitary administration of low-dose IL-2 in a case series of 100 cancer patients with neoplastic effusions. Methods: One hundred patients with advanced solid tumors and neoplastic effusions underwent IL-2 intracavitary injection as first-line treatment. The most common sites of fluid accumulation were pleura (n = 68), peritoneum (n = 21) and pericardium (n = 11). Breast cancer, lung cancer and mesothelioma were the most frequent neoplasms in our series. One cycle consisted of intracavitary IL-2 at 6,000,000 IU on days 1 and 7. Results: According to Paladine’s criteria, an objective clinical response was achieved in 72% (complete response in 27% and partial response in 45%), with a median duration of 5 months (range: 1–11 months). The peritoneum was the least responsive site for neoplastic effusion reduction. IL-2 intracavitary injection was well tolerated in all patients; the only toxicity observed was fever >38°C in 6% of the patients. Conclusion: This study shows that intracavitary injection of IL-2 represents a feasible, well-tolerated and effective therapy of neoplastic fluid accumulation. Further studies are needed in order to compare the effectiveness of intracavitary IL-2 with other standard treatments.

show abstract

Intrapleural Natural Beta Interferon in the Treatment of Malignant Pleural Effusions

Cited by 75 publications

References 3 publications

Management of malignant pleural effusions

Management of malignant pleural effusions

Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study

Progress Report on the Palliative Therapy of 100 Patients with Neoplastic Effusions by Intracavitary Low-Dose Interleukin-2

Contact Info

Product

Resources

About